Engineering Chimeric Antigen Receptors for Cancer Immunotherapy

Wed3  Sep02:30pm(30 mins)
Charter 3
 David Gilham


There has been an explosion of interest in immune therapies for cancer. This interest has been initially driven by monoclonal antibodies and is now being carried on by cellular regenerative medicines. Gene modified T-cells in particular are achieving impressive responses in early phase clinical trials which has stimulated Industrial involvement in a field fairly recently considered unlikely to be attractive to Pharma. Gene modified T-cells fall into two broad schemes; one where a recombinant T-cell receptor is expressed to exploit the natural activation pathways of the T-cell. The second is the Chimeric Antigen Receptor (CAR) which is an artificial protein based upon antibody technology that effectively circumvents the natural restrictions that are imposed upon the T-cell and also avoids some of the mechanisms employed by tumours to avoid T-cell mediated elimination. During this talk, key features associated with the engineering of CAR’s will be discussed as well as the implications of CAR design and ex vivo T-cell culture upon the current and future delivery of this technology.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021